Cargando…

Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice

The 2014 Ebola outbreak in West Africa resulted in more than 11,000 deaths, highlighting the need for a vaccine. A phase I clinical trial of a human adenovirus type 5 vector-based Ebola virus (EBOV) vaccine (HAdV-5-MakGP) showed that a homologous prime-boost regimen with HAdV-5 vaccine elicited a ro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Wei, Zhang, Peng, Bai, Shuang, Lv, Min, Wang, Jian, Chen, Weixin, Yu, Qingzhong, Wu, Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482741/ https://www.ncbi.nlm.nih.gov/pubmed/34591172 http://dx.doi.org/10.1007/s00705-021-05234-4

Ejemplares similares

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Epidemical features of HAdV-3 and HAdV-7 in pediatric pneumonia in Chongqing, China
por: Wo, Ying, et al.
Publicado: (2014)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques
por: Yang, Xi, et al.
Publicado: (2019)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Human Adenovirus (HAdV) Viremia in Immunocompetent Children with HAdV Infection in Respiratory Specimens: Does Viremia Predict Severity of Illness?
por: Song, Eunkyung, et al.
Publicado: (2017)

1138 Human Adenovirus (HAdV) Blood Viral Detection is Associated with Higher Viral Load in Immunocompetent Pediatric HAdV Respiratory Samples
por: Song, Eunkyung, et al.
Publicado: (2014)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Molecular Evolution of Human Adenovirus (HAdV) Species C
por: Dhingra, Akshay, et al.
Publicado: (2019)

Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques
por: Lorin, Clarisse, et al.
Publicado: (2015)

Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens
por: Tan, Wendy G., et al.
Publicado: (2017)

Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice
por: Andersson, Anne-Marie Carola, et al.
Publicado: (2016)

HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model
por: Toth, Karoly, et al.
Publicado: (2017)

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
por: Heinen, Natalie, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease
por: Peng, Shiwen, et al.
Publicado: (2016)

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
por: Ba, Lei, et al.
Publicado: (2007)

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
por: Sablerolles, Roos S. G., et al.
Publicado: (2021)

Intestinal HAdV Infection: Tissue Specificity, Persistence, and Implications for Antiviral Therapy
por: Kosulin, Karin
Publicado: (2019)

PML Alternative Splice Products Differentially Regulate HAdV Productive Infection
por: Mai, Julia, et al.
Publicado: (2022)

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens
por: Jiang, Hu-Dachuan, et al.
Publicado: (2022)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
por: Crooks, Emma T., et al.
Publicado: (2021)

Elicitation of Both Anti HIV-1 Env Humoral and Cellular Immunities by Replicating Vaccinia Prime Sendai Virus Boost Regimen and Boosting by CD40Lm
por: Zhang, Xianfeng, et al.
Publicado: (2012)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Human adenoviral (HAdV) chronic arthritis expands the infectious spectrum of primary agammaglobulinemia
por: de Frémont, Grégoire Martin, et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
por: Klemis, Verena, et al.
Publicado: (2022)

Fusion-Expressed CTB Improves Both Systemic and Mucosal T-Cell Responses Elicited by an Intranasal DNA Priming/Intramuscular Recombinant Vaccinia Boosting Regimen
por: Qiu, Sugan, et al.
Publicado: (2014)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g81k2r9fkllgkkbb5tpf8eur72